Crescent Biopharma, Inc.
NASDAQ:CBIO · NASDAQ Capital Market
-$0.49 today
Vol 0.11M · Avg 0.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-75.8%
avg -26.6%
ROIC
-74.6%
avg -72.7%
ROA
-64.1%
avg -59.7%
Analysis
ROA is currently the strongest return metric at -64.1% versus its period average of -59.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joshua T. Brumm | Chief Executive Officer & Director | $1.25M | — | 48 | $323,517.00 | 1.17% |
Jonathan McNeill | President & Chief Operating Officer | $871,682.00 | — | 41 | $11,050.00 | 0.04% |
Ellie Im | Chief Medical Officer | $847,841.00 | — | 48 | $65,190.00 | 0.24% |
Wenjie Cheng | Senior Vice President of Technical Operations | — | — | — | — | — |
Richard William Scalzo | Chief Financial Officer | — | — | 40 | $57,688.00 | 0.21% |
Ryan Lynch | Senior Vice President of Finance, Treasurer & Chief Accounting Officer | — | — | 42 | $33,512.00 | 0.12% |
Christopher Doughty | Chief Business Officer | — | — | 38 | $58,855.00 | 0.21% |
Barbara H. Bispham | General Counsel & Corporate Secretary | — | — | 39 | $72,185.00 | 0.26% |
Amy Reilly | Chief Communications Officer | — | — | 52 | — | — |
Jan Pinkas | Chief Scientific Officer | — | — | 57 | $70,025.00 | 0.25% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$18.24M
Sells
0
$0.00
Net Sentiment
+$18.24M
Net buying
Most Active
Fairmount Funds Management LLC
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | Fairmount Funds Management LLC Indirect | Buy | 1.36M | $13.41 | $18,237,600.00 | |
| Dec 4, 2025 | Fairmount Funds Management LLC Indirect | Buy | 131.4K | $0.00 | $131.43 |
Analysis
Insiders reported 2 buys worth $18.24M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $18.24M. Fairmount Funds Management LLC was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +9.6% | +9.4% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +9.6% over three years. Forward estimates point to Revenue at +9.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
C4 Therapeutics, Inc.
NASDAQ:CCCC
$330.07M
OmniAb, Inc.
NASDAQ:OABI
$257.83M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$253.67M
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
$191.29M
Compugen Ltd.
NASDAQ:CGEN
$188.63M
Innate Pharma S.A.
NASDAQ:IPHA
$169.96M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$143.33M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$72.87M
Heron Therapeutics, Inc.
NASDAQ:HRTX
$63.11M
Vyome Holdings, Inc.
HIND
$12.61M
Who manages CBIO?
Crescent Biopharma, Inc. (CBIO) lists 10 active executives. The top listed executive is Jonathan McNeill, President & Chief Operating Officer.
Are CBIO insiders buying or selling?
Recent insider activity shows net buying of $39.99M.
Explore More
Continue the stock analysis
Jump to another research area for this company.